High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation

Journal of Hepatology

Volumn 30, Issue 4, 1999, Pages 715-721

  Mutimer, David ^a   Pillay, Deenan ^b,e   Dragon, Elizabeth ^c   Tang, Howard ^a   Ahmed, Monz ^a   O'Donnell, Katharina ^a   Shaw, Jean ^a   Burroughs, Nigel ^d   Rand, David ^d   Cane, Patricia ^b   Martin, Brian ^b   Buchan, Sandy ^b   Boxall, Elizabeth ^e   Barmat, Scott ^c   Gutekunst, Karen ^c   McMaster, Paul ^a   Elias, Elwyn ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c HOFFMANN LA ROCHE INC   (United States)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Drug resistance; Hepatitis B virus; Lamivudine; Liver transplantation

Indexed keywords

LAMIVUDINE;

ARTICLE; CLINICAL ARTICLE; GRAFT INFECTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RECURRENT INFECTION; REINFECTION; TREATMENT FAILURE;

EID: 0033035335     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80204-9     Document Type: Article

References (21)

1. Muller R., Gubernatis G., Farle M., Niehoff G., Klein H., Wittekind C., et al. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B recurrence by passive immunisation. J Hepatol. 13:1991;90-96.
2. Samuel D., Muller R., Alexander G., Fassati L., Ducot B., Benhamou J-P, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 329:1993;1842-1847.
3. Wallace L.A., Carman W.F. Surface gene variation of HBV: scientific and medical relevance. Viral Hepat Rev. 3:1997;5-16.
4. Harrison R.F., Davies M.H., Goldin R.D., Hubscher S.G. Recurrent hepatitis B in liver allografts: a distinctive form of rapidly developing cirrhosis. Histopathology. 23:1993;21-28.
5. Davies S.E., Portmann B.C., O'Grady J.G., Aldis P.M., Chaggar K., Alexander G.J.M., et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 13:1991;150-157.
6. Wiesner R.H., Krom R.A.F. Liver transplantation for hepatitis B: the con aspect. Liver Transplant Surg. 1:1995;265-270.
7. Nevens F., Main J., Honkoop P., Tyrrell D.L., Barber J., Sullivan M.T., et al. Lamivudine therapy for chronic hepatitis B: a six-month randomised dose-ranging study. Gastroenterology. 113:1997;1258-1263.
8. Dienstag J.L., Perrillo R.P., Schiff E.R., Bartholomew M., Vicary C., Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 333:1995;1657-1661.
9. Mutimer D.J., Tang H., Dragon E., Gutekunst K., Barmat S., Ahmed M., et al. Antiviral treatment of chronic hepatitis B virus (HBV) infection: assessment of response using a sensitive quantitative polymerase chain reaction (PCR) assay. [abstract] Gastroenterology. 112:1997;A1341.
10. Grellier L., Mutimer D., Ahmed M., Brown D., Burroughs A., Rolles K., et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet. 348:1996;1212-1215.
11. Ling R., Mutimer D.J., Ahmed M., Boxall E.H., Elias E., Dusheiko G., et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 24:1996;711-713.
12. Tipples G.A., Ma M.M., Fischer K.P., Bain V.G., Kneteman N.N., Tyrrell D.L.J. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 24:1996;714-717.
13. Bartholomew M.M., Jansen R.W., Jeffers L.J., Reddy K.R., Johnson L.C., Buzendahl H., et al. Hepatitis B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet. 349:1997;20-22.
14. Chayama K., Suzuki Y., Kobayashi M., Kobayashi M., Tsubota A., Hashimoto M., et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild-type after cessation of therapy. Hepatology. 27:1998;1711-1716.
15. Nowak M.A., Bonhoeffer S., Hill A.M., Boehme R., Thomas H.C., McDade H. Viral dynamics in hepatitis B virus infection. PNAS. 93:1996;4398-4402.
16. Zeuzem S., de Man R.A., Honkoop P., Roth W.K., Schalm S.W., Schmidt J.M. Dynamics of hepatitis B virus infection in vivo. J Hepatol. 27:1997;431-436.
17. Mansky L.M., Temin H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 69:1995;5087-5094.
18. Monk R.J., Malik F.G., Stokesberry D., Evans L.H. Direct determination of the point mutation rate of a murine retrovirus. J Virol. 66:1992;3683-3689.
19. Varela-Echavarria A., Garvey N., Preston B.D., Dougherty J.P. Comparison of Moloney murine leukaemia virus mutation rate with the fidelity of its reverse transcriptase in vitro. J Biol Chem. 267:1992;24681-24688.
20. Kareem A.M.A., Blow O., Gaffey M.J., Iezzoni J.C., McGory R.W., Pruett T.L. Immunohistochemical positivity for HBsAg and HBcAg of liver biopsy is not predictive of recurrence in patients treated with HBV immune globulin. [abstract] Hepatology. 24:1996;283A.
21. Markowitz J.S., Martin P., Conrad A.J., Markmann J.F., Seu P., Yersiz H., et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 28:1998;585-589.